OCUL
Ocular Therapeutix, Inc.
OCUL lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow.
OCUL Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
OCUL's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
OCUL PE Valuation
OCUL has no meaningful PE right now: it lost money over the past year.
OCUL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect OCUL's losses to grow, with revenue growing.
OCUL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.44 | -$0.04 |
| Q2 2026 | -$1.40 | -$0.16 |
| Q1 2026 | -$1.44 | -$0.33 |
| Q4 2025 | -$1.42 | -$0.20 |
| Q3 2025 | -$1.40 | -$0.31 |
| Q2 2025 | -$1.24 | -$0.12 |
| Q1 2025 | -$1.11 | +$0.01 |
| Q4 2024 | -$1.22 | -$0.20 |
OCUL is still losing money, but less than at its worst: $1.44 per share over the past year, against $2.56 at its worst in late 2020.
OCUL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $12.9M | -11% |
| Q2 2026 | $13.5M | +0.1% |
| Q1 2026 | $10.8M | +0.8% |
| Q4 2025 | $13.3M | -22% |
| Q3 2025 | $14.5M | -5.7% |
| Q2 2025 | $13.5M | -18% |
| Q1 2025 | $10.7M | -28% |
| Q4 2024 | $17.1M | +15% |
OCUL's revenue has slid since its 2024 peak: $13M last quarter, down 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -760% | -288 points |
| Q2 2026 | -609% | -107 points |
| Q1 2026 | -865% | -268 points |
| Q4 2025 | -526% | -230 points |
| Q3 2025 | -472% | -174 points |
| Q2 2025 | -503% | -237 points |
| Q1 2025 | -597% | -384 points |
| Q4 2024 | -296% | -161 points |
OCUL's operating margin was −760% last quarter, down 288 points from the same quarter a year ago.
OCUL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$68.7M | -$11.9M |
| Q2 2026 | -$70.6M | -$14.2M |
| Q1 2026 | -$70.7M | -$24.1M |
| Q4 2025 | -$57.1M | -$17.5M |
| Q3 2025 | -$56.7M | -$20.1M |
| Q2 2025 | -$56.5M | -$30.9M |
| Q1 2025 | -$46.6M | -$12.5M |
| Q4 2024 | -$39.6M | -$16.7M |
OCUL has burned cash in almost every quarter: −$267M over the past year, against −$199M the year before.
OCUL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +563K shares |
| 1 year | +23% | +41.6M shares |
| 3 years | +189% | +147M shares |
| 5 years | +175% | +143M shares |
| Available history | +398% | +180M shares |
OCUL has 226M diluted shares, up 23% from a year ago.
OCUL Net Leverage
OCUL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OCUL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.5 | Neutral |
| Stochastic | 10.7 | Oversold |
OCUL's weekly RSI is 36 (neutral) and its Stochastic is 11 (oversold).
OCUL PE vs Healthcare Sector
OCUL has no meaningful PE right now: it lost money over the past year.
OCUL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.17 | 12% below |
| 20 week MA | $8.73 | 28% below |
| 50 week MA | $9.37 | 33% below |
| 100 week MA | $9.49 | 34% below |
| 200 week MA | $7.82 | 20% below |
OCUL is in a downtrend: it's below all five of its weekly moving averages, and 20% below its 200-week average.
OCUL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.19 | $22.1 | +427% |
| 2021 | $22.1 | $7.22 | -67% |
| 2022 | $7.22 | $2.67 | -63% |
| 2023 | $2.67 | $4.46 | +67% |
| 2024 | $4.46 | $8.44 | +89% |
| 2025 | $8.44 | $12.6 | +49% |
| 2026 YTD | $12.6 | $6.28 | -50% |
OCUL's yearly returns have swung widely, from +427% in 2020 to −67% in 2021. It's down 50% so far in 2026.